Dr. Chris Stout: Pandemic Update – March 3, 2021 LinkedIn 3/3/2021 © Provided by LinkedIn
Welcome to this Week’s Edition – A Convenient Digest and Curated Collection of Verified News and Studies Related to Global Health and Humanitarian Intervention
The most likely timeline for life to return to normal
At long last, Americans are able to see the relief on the horizon, and the end of the outbreak that’s cost the country more than 500,000 lives.
Popular Searches
this spring will not be substantially different from the past year;
summer could, miraculously, be close to normal; and
next fall and winter could bring either continued improvement or a moderate backslide, followed by a near-certain return to something like pre-pandemic life.”
More states are easing Covid-19 restrictions, even as health experts sound warnings
localnews8.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from localnews8.com Daily Mail and Mail on Sunday newspapers.
The country needs to hold on for another 2 or 3 months without easing up, experts say
msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.
LA Schools To Launch Microsoft COVID-Tracking App So Children Can Attend Classes
zerohedge.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from zerohedge.com Daily Mail and Mail on Sunday newspapers.
POLITICO
Drug industry pushes FDA to solve growing inspection backlog
Inspections are a vital tool to ensure the safety of new drugs as well as medicines already on the market.
Food And Drug Administration inspectors have been unable to travel as extensively as they need to. | Sarah Silbiger/Getty Images
By SUZANNE SMALLEY
Link Copied
The Food and Drug Administration is under increasing pressure from the pharmaceutical industry to address the growing backlog of drug inspections nearly a year after Covid-19 prompted the agency to halt most plant visits.
From March through September, FDA inspected just three plants outside the U.S., well below the 600-plus it visited in each of the prior two years, the Government Accountability Office said last month. FDA has also struggled to keep up with inspections within U.S. borders, conducting just 52 during the same seven-month period last year, compared with roughly 400 each in 2019 and 2018.